Bictegravir-lenacapavir single-tablet regimen non-inferior to complex regimens for HIV-1 suppression at 48 weeks Can a single daily pill control HIV as well as complex multi-pill regimens?

In this phase 3 randomized trial of 557 virologically suppressed adults with HIV-1 on complex regimens, switching to once-daily oral bictegravir-lenacapavir was non-inferior to continuing complex regimens for maintaining virological suppression at week 48 (1% vs 1%). Adverse event rates were similar between groups. These findings suggest this single-tablet regimen may be an option for treatment simplification in this population.

For people living with HIV who have been on complex, multi-pill regimens for years, a simpler option may work just as well. A new study found that switching to a single daily pill kept the virus suppressed just as effectively as staying on the more complicated treatment after one year. This offers a potential path to a simpler daily life, but the long-term safety of the new pill is still being studied.